Pfizer is falling short in a competitive market, Johnson & Johnson says as it hits back at Remicade biosimilar suit
admin 26th September 2017 Uncategorised 0Pfizer last week sued Big Pharma peer Johnson & Johnson for “anticompetitive” contracting on blockbuster Remicade that’s limiting uptake of a discounted biosimilar. Now, taking its case straight to patients and the public, J&J says its exclusive contracts are not anticompetitive but in fact driving down the cost of healthcare.
More: Pfizer is falling short in a competitive market, Johnson & Johnson says as it hits back at Remicade biosimilar suit
Source: fierce